george b abercrombie  executive bio compensation history and contacts  equilar atlas   log in  sign up x   as featured in george b abercrombie former senior vice president and chief commercial officer at innoviva inc view full profile are you george b abercrombie claim your profile   sign up for equilar atlas and view george b abercrombies full profile with equilar atlas you can identify corporate executives in george b abercrombies network and community follow changes in george b abercrombies employment and moneyinmotion connect with george b abercrombie through your network of contacts george b abercrombies executive work history past to view george b abercrombies complete executive work history sign up now education bs university of north carolina  chapel hill mba harvard university age      george b abercrombies biography george b abercrombie was appointed to the board in october  and was elected chairman of the board in may  mr abercrombie has over  years of experience as a business leader in the pharmaceutical industry he most recently served from  to  as the president and chief executive officer of hoffmannla roche inc a pharmaceutical company where he was responsible leading operations in both the us and canada during his tenure mr abercrombie also served as a member of the roche pharmaceutical executive committee which was responsible for developing and implementing global strategy for the pharmaceuticals division in   read more george b abercrombie was appointed to the board in october  and was elected chairman of the board in may  mr abercrombie has over  years of experience as a business leader in the pharmaceutical industry he most recently served from  to  as the president and chief executive officer of hoffmannla roche inc a pharmaceutical company where he was responsible leading operations in both the us and canada during his tenure mr abercrombie also served as a member of the roche pharmaceutical executive committee which was responsible for developing and implementing global strategy for the pharmaceuticals division in  mr abercrombie joined glaxo wellcome inc as vice president and general manager of the glaxo pharmaceuticals division and was later promoted to senior vice president us commercial operations prior to joining glaxo he spent over ten years at merck  co inc where he gained experience in sales and marketing executive sales management and business development mr abercrombie began his career as a pharmacist after receiving a bachelors degree in pharmacy from the university of north carolina at chapel hill and later earned an mba from harvard university mr abercrombie currently holds the position of senior vice president and chief commercial officer at innoviva inc a publicly traded biopharmaceutical asset management company he also serves as on the board of brickell biotech a private pharmaceutical company he formerly served on the boards of directors of inspire pharmaceuticals inc ziopharm oncology inc tranzyme pharma aptus health inc and demerx additionally he is an adjunct professor at duke universitys fuqua school of business and a board member of the north carolina glaxosmithkline foundation he previously served on the executive committee and board of directors of the pharmaceutical research  manufacturers of america phrma as well as on the board of the johns hopkins school of hygiene and public health mr abercrombies executive experience in the pharmaceutical industry and management positions with major pharmaceutical companies provide an excellent background for service on the board source biocryst pharmaceuticals inc on    sign up for equilar atlas and view george b abercrombies full profile by accessing equilar atlas you can view bios network salary and wealth events of industryleading executives like george b abercrombie more specifically youll be able to identify corporate executives in george b abercrombies network and community follow changes in george b abercrombies employment and moneyinmotion connect with george b abercrombie through your network of conections view full profile   search for over  executive profiles bio example george b abercrombie george b abercrombies connections  sign up now to view george b abercrombies  connections » wyche fowler board member ziopharm oncology inc robert a ingram chairman of the board biocryst pharmaceuticals inc zola p horovitz former board member palatin technologies inc fong w clow former senior vp development paratek pharmaceuticals inc frank pasqualone svp chief comm ops officer theravance biopharma inc alane p barnes vice president general counsel and corporate secretary biocryst pharmaceuticals inc michael e faerm senior vice president and chief business officer innoviva inc stuart r grant former executive vice president and chief financial officer patheon nv william p sheridan senior vice president and chief medical officer biocryst pharmaceuticals inc murray f brennan board member ziopharm oncology inc popular profiles sign up now to view more executive profiles » thomas j lynch executive chairman te connectivity ltd john j kita evp and cfo a o smith elon r musk ceo and chairman tesla claiborne p deming chairman of the board murphy oil corporation daniel a dematteo executive chairman gamestop corp × claim your profile coming soon interested in updating your biography and work history were working on making it happen well email you when this feature is available please enter valid email address done thank you for your interest ok browse executive profiles  a  b  c  d  e  f  g  h  i  j  k  l  m  n  o  p  q  r  s  t  u  v  w  x  y  z equilar homepage equilar atlas equilar insight equilar boardedge equilar engage research services knowledge network about us login �  equilar all rights reserved privacy policy  marshall street redwood city ca   phone    fax   ziopharm elects george b abercrombie former ceo of hoffmannla roche to board of directors nasdaqziop facebook google linkedin twitter email rss apr   previous release  next release pdf ziopharm elects george b abercrombie former ceo of hoffmannla roche to board of directors  dr murray brennan named chairman of board  new york apr   business wire  ziopharm oncology inc nasdaq ziop announced today the appointment of george b abercrombie to its board of directors mr abercrombie will serve as a member of the boards compensation committee as well as the nominating and corporate governance committee additionally dr murray brennan was elected chairman of the board mr abercrombie most recently served as the president and chief executive officer of hoffmannla roche roche north america and has more than  years experience in the pharmaceutical industry he was responsible for roches us and canadian pharmaceuticals business under mr abercrombies leadership the value of roches us business increased achieving leading market share positions for key marketed products in joining the ziopharm board george will also have the opportunity to continue his relationship with dr larry norton a consultant partner to ziopharm with whom he worked closely at roche and while dr norton was the president of asco prior to joining hoffmannla roche inc in  mr abercrombie held the position of senior vice president commercial operations at glaxo wellcome inc and prior to joining glaxo held progressively senior positions at merck and company in mercks human health division in the united states during his distinguished career he has testified as an expert witness on numerous occasions in front of both houses of the us congress mr abercrombie began his career as a pharmacist after receiving a bachelors degree in pharmacy from the university of north carolina and earned his mba from harvard university he has served on many boards and organizations throughout his career including the phrma pharmaceutical research and manufacturers of america board of directors the johns hopkins school of hygiene and the public health advisory project hope board of directors and the duke university fuqua school of business health sector advisory board among others given georges extensive knowledge and understanding of the development and commercialization of pharmaceutical products across a wide range of indications including those for cancerrelated therapies he will be an invaluable addition to the ziopharm team stated dr murray brennan chairman of the board ziopharm will no doubt benefit from georges wisdom and experience and we are extremely pleased to have him on board at this important transformational stage of the companys growth and development this is really an exciting time for ziopharm and me i am thrilled to be joining this team of enormously impressive professionals who are developing promising medicines to treat cancer commented mr abercrombie i look forward to contributing to ziopharms success as we build value for patients shareholders and the healthcare system about ziopharm oncology inc ziopharm oncology is a biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of cancer drugs the company is currently focused on three clinical programs palifosfamide zymafostm or zio references a novel composition tris formulation that comprises the functional active metabolite of ifosfamide a standard of care for treating sarcoma lymphoma testicular and other cancers palifosfamide delivers only the cancer fighting component of ifosfamide it is expected to overcome the resistance seen with ifosfamide and cyclophosphamide two of the most commonly used dnaalkylating drugs used to treat cancers palifosfamide does not have the toxic metabolites of ifosfamide that cause the debilitating side effects of fuzzy brain encephalopathy and severe bladder inflammation it may also have other advantages intravenous palifosfamide is currently in a randomized phase ii trial to treat unresectable or metastatic soft tissue sarcoma in the front and secondline setting with the company having reported interim positive results in late  a registration trial in the same setting is expected to initiate following us food and drug administration fda review in the first half of this year an oral form of palifosfamide has been developed preclinically to the investigational new drug application stage darinaparsin zinapartm or zio is a novel mitochondrialtargeted agent organic arsenic being developed for the treatment of various hematologic and solid cancers preclinical and clinical studies to date have demonstrated that darinaparsin is considerably less toxic than inorganic arsenic particularly with regard to cardiac toxicity the company has reported favorable results from a phase ii trial with ivadministered darinaparsin in lymphoma particularly peripheral tcell lymphoma ptcl at the american society of clinical oncology asco in may of  which would serve as the basis for ongoing clinical study in ptcl following regulatory review and available financial resources phase i trials with the oral form are ongoing in both hematological malignancies and solid tumors indibulin zybulintm or zio is a novel oral tubulin binding agent that targets both mitosis and cancer cell migration in addition indibulin is expected to have several potential benefits including oral dosing application in multidrug resistant tumors no neuropathy and minimal overall toxicity in multiple phase i trials in cancer patients oral indibulin has been administered both as a single agent and in combination with favorable activity and a promising safety profile that does not include the neurotoxicity seen with all of the other classes of tubulin binding agents most recently results of oral indibulin in combination with oral capecitabine xelodar were presented at last years american society of clinical oncology asco along with the preclinical findings of a novel dosing schedule conducted under the direction of dr larry norton employing this dosage schedule the company expects to initiate a phase i study early this year in breast cancer patients with the breast team at memorial sloan kettering ziopharms operations are located in boston ma with an executive office in new york city further information about ziopharm may be found at wwwziopharmcom ziopg forwardlooking safe harbor statement this press release contains forwardlooking statements for ziopharm oncology inc that involve risks and uncertainties that could cause the companys actual results to differ materially from the anticipated results and expectations expressed in these forwardlooking statements these statements are based on current expectations forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements among other things there can be no assurance that any of the companys development efforts relating to its product candidates will be successful or such product candidates will be successfully commercialized other risks that affect forwardlooking information contained in this press release include the possibility of being unable to obtain regulatory approval of the companys product candidates the risk that the results of clinical trials may not support the companys claims the risk that preclinical or clinical trials will proceed on schedules that are consistent with the companys current expectations or at all risks related to the companys ability to protect its intellectual property and its reliance on third parties to develop its product candidates risks related to the sufficiency of existing capital reserves to fund continued operations for a particular amount of time and uncertainties regarding the companys ability to obtain additional financing to support its operations thereafter the company assumes no obligation to update these forwardlooking statements except as required by law source ziopharm oncology inc ziopharm oncology inctyler cook tcookziopharmcomormediadennis s dobson dsdobsonoptonlinenet copyright business wire  theravance inc appoints george b abercrombie as senior vice president corporate partnerships commercialhomemailflickrtumblrnewssportsfinancecelebrityanswersgroupsmobilemoretry yahoo finance on firefox »yahoosearchsearchsign inus markets open in  hr  minssp futures dow futures nasdaq futures theravance inc appoints george b abercrombie as senior vice president corporate partnerships commercialmarketwiredjune  reblogsharetweetsharesouth san francisco camarketwired  jun    theravance inc  nasdaq  thrx  theravance a royalty management company today announced the appointment of george b abercrombie senior vice president corporate partnerships commercial mr abercrombie will report directly to rick e winningham chief executive officer and be responsible for working closely with theravances partners to achieve optimal results from the commercialization of the assets shared by the companies in particular mr abercrombie will be focused on the global launches of relvar®breo® ellipta® and anoro™ ellipta® and ongoing development activities with other respiratory programs partnered with glaxo group limited gskwith more than  years of experience as a business leader in the pharmaceutical industry mr abercrombie joins theravance after serving as the president and chief executive officer of hoffmannla roche inc from  to  where he was responsible for the us and canada prior to that mr abercrombie worked at glaxo and its successor companies from  to  including as senior vice president of commercial operations for glaxo wellcome inc with full pl responsibility for all marketing sales managed care state government affairs ecommerce disease management business planning and development and phase b clinical studies over the period  to  mr abercrombie was most recently elected as chairman of the board of biocryst pharmaceuticals inc and also serves as a board member of numerous other healthcarerelated organizations including project hope and the north carolina glaxosmithkline foundation mr abercrombie holds an mba from harvard business school and a bs from the university of north carolina at chapel hill school of pharmacyas we continue to build out our new leadership team at theravance im pleased to welcome george as a prominent and experienced executive in the pharmaceutical industry who will play a significant role in shaping our corporate strategy and collaborating with our partners said rick e winningham chief executive officer of theravance george brings deep therapeutic area product development and commercialization perspective to theravance which will be critical in maximizing the value of our partnered assets and help provide capital returns to our stockholdersabout theravancetheravance inc a royalty management company is focused on maximizing the potential value of the respiratory assets partnered with glaxo group limited gsk including relvar®breo® ellipta® and anoro™ ellipta® with the intention of providing capital returns to stockholders under the longacting beta agonist laba collaboration agreement with gsk theravance is eligible to receive the associated royalty revenues from relvar®breo® ellipta® fluticasone furoatevilanterol ffvi anoro™ ellipta® umeclidinium bromidevilanterol umecvi and if approved and commercialized vi monotherapy theravance is also entitled to a  economic interest in any future payments made by gsk relating to the combination of umecviff and the bifunctional muscarinic antagonistbeta agonist maba program as monotherapy and in combination with other therapeutically active components such as an inhaled corticosteroid and any other product or combination of products that may be discovered and developed in the future under its laba collaboration agreement with gsk other than relvar®breo® ellipta® anoro™ ellipta® and vi monotherapy for more information please visit theravances web site at wwwthrxinccomrelvar® breo® anoro™ and ellipta® are trademarks of the glaxosmithkline group of companiesforwardlooking statementsthis press release contains certain forwardlooking statements as that term is defined in the private securities litigation reform act of  regarding among other things statements relating to goals plans objectives and future events theravance intends such forwardlooking statements to be covered by the safe harbor provisions for forwardlooking statements contained in section e of the securities exchange act of  and the private securities litigation reform act of  examples of such statements include statements relating to the strategies plans and objectives of the company following the separation the timing manner amount and planned growth of anticipated potential capital returns to stockholders including without limitation statements concerning the intention to initiate a cash dividend in the third quarter of  expectations of future cash dividend growth and the potential for future share repurchases the status and timing of clinical studies data analysis and communication of results the potential benefits and mechanisms of action of product candidates expectations for product candidates through development and commercialization the timing of seeking regulatory approval of product candidates and projections of revenue expenses and other financial items these statements are based on the current estimates and assumptions of the management of theravance as of the date of this press release and are subject to risks uncertainties changes in circumstances assumptions and other factors that may cause the actual results of theravance to be materially different from those reflected in the forwardlooking statements important factors that could cause actual results to differ materially from those indicated by such forwardlooking statements include among others risks related to the disruption of operations during the transition period following the spinoff including the diversion of managements and employees attention disruption of relationships with collaborators and increased employee turnover lower than expected future royalty revenue from respiratory products partnered with gsk delays or difficulties in commencing or completing clinical studies the potential that results from clinical or nonclinical studies indicate product candidates are unsafe or ineffective dependence on third parties to conduct its clinical studies delays or failure to achieve and maintain regulatory approvals for product candidates and risks of collaborating with third parties to discover develop and commercialize products other risks affecting theravance are described under the heading risk factors contained in theravances quarterly report on form q filed with the securities and exchange commission sec on may   and the risks discussed in theravances other periodic filings with the sec given these uncertainties you should not place undue reliance on these forwardlooking statements theravance assumes no obligation to update its forwardlooking statementsthrxgreblogsharetweetsharerecently viewedyour list is emptywhat to read nextviacom taps justin dini to be svp corporate communicationsdeadlineengineer finds pattern makes millions in stocksmoney morningsponsoredgrab builds out war chest in a fight for carshare dominanceassociated presscowboys hope to have extension for zack martin before camp endsprofootball talk on nbc sportsheres trumps approval rating in every statebusiness insiderstart earning miles with the best travel cardwise breadsponsoredparents railed against the boy scouts of america after trumps campaignstyle speechbusiness insiderthe navys newest most sophisticated aircraft carrier doesnt have urinalsbusiness insidergm to consider axing six models to combat slumping sales avoid plant layoffsthe streetdog gets on bus alone every day without ownernews daily feedsponsoredchina is crushing american tech titansyahoo finance videomcdonalds gm and dominos — what you need to know in markets on tuesdayyahoo financefirst ‘avengers infinity war’ trailer leakedinvestorplacehitlers final bunker broken into by photographertrend chasersponsoredobamacare is hurting these people—and congress is doing nothing about ityahoo financeunder armour ripped up jordan spieths old contract before he won his first major and gave him a year deal and its already paid off big timebusiness insidertrump’s kellyanne conway ought to be fired says bush ethics chiefesportech trump and many of his appointees such as conway have made a complete mockery out of the office of the us presidency she has no class no dignity and no ethicsjoin the conversation   biocryst pharmaceuticals inc  board of directors homeabout biocrystcompany overviewpartners  business developmentleadership teamboard of directorscorporate governancecommittee compositioncode of business conductcommittee charterscareersopportunitiesour sciencepipeline  productrapivabnext generation kallikrein inhibitors for haebcxinvestorsanalyst coverageevents  presentationsemail alertsfinancial profileinvestor faqinformation requestnewsproxy onlinesec documentsstock informationcontact irnews  resourceslatest newshae publicationsbcx publications board of directors home  contact us  site map go print this page board of directors board of directors george b abercrombie fred e cohen md dphil stanley c erck nancy hutson phd robert a ingram kenneth b lee jr sanj k patel jon p stonehouse robert a ingram chairman of the board robert a ingram was appointed to the board in august  and was elected chairman of the board in may  mr ingram joined hatteras venture partners a venture capital firm formed to invest primarily in early stage companies with a focus on biopharmaceuticals medical devices diagnostics healthcare it and related opportunities in human medicine as a general partner in january  he began his career in the pharmaceutical industry as a professional sales representative and rose through a series of roles with increasing responsibility to ultimately become ceo and chairman of glaxowellcome a pharmaceutical company he coled the merger and integration that formed glaxosmithkline gsk in december  he subsequently served as the chief operating officer and president of pharmaceutical operations at gsk from january  to january  he served as vice chairman pharmaceuticals of gsk acting as a special advisor to gsk’s corporate executive team until january   mr ingram serves as chairman of the board of novan inc a pharmaceutical company and as lead independent director of cree inc a manufacturer of semiconductor lightemitting diode materials and devices mr ingram also serves as a member of the board of directors of hbm healthcare investments ltd a publicly traded swiss investment company and of malin corporation plc a publicly traded life sciences company based in ireland mr ingram also serves as chairman of viamet pharmaceuticals inc a private company focused on antiinfective research and a director of phasebio pharmaceuticals inc a private clinicalstage biopharmaceutical company mr ingram graduated from eastern illinois university with a bs degree in business administration in addition to his professional responsibilities mr ingram formed and chaired the ceo roundtable on cancer at the request of former president george h w bush and he is a member of numerous other civic and professional organizations mr ingram is a member of the boards for the james b hunt jr institute for educational leadership and policy ceo roundtable on cancer research triangle institute research triangle foundation and chairman north carolina glaxosmithkline foundation mr ingram’s extensive experience in the pharmaceutical industry as both an executive and director and his private investment expertise contribute valuable insight and expertise to the board back to top george b abercrombie george b abercrombie was appointed to the board in october  mr abercrombie has over  years of experience as a business leader in the pharmaceutical industry he most recently served from  to  as the president and chief executive officer of hoffmannla roche inc a pharmaceutical company where he was responsible leading operations in both the us and canada during his tenure mr abercrombie also served as a member of the roche pharmaceutical executive committee which was responsible for developing and implementing global strategy for the pharmaceuticals division in  mr abercrombie joined glaxo wellcome inc as vice president and general manager of the glaxo pharmaceuticals division and was later promoted to senior vice president us commercial operations prior to joining glaxo he spent over ten years at merck  co inc where he gained experience in sales and marketing executive sales management and business development mr abercrombie began his career as a pharmacist after receiving a bachelor’s degree in pharmacy from the university of north carolina at chapel hill and later earned an mba from harvard university mr abercrombie currently holds the position of senior vice president and chief commercial officer at innoviva inc a publicly traded biopharmaceutical asset management company he also serves on the board of brickell biotech a private pharmaceutical company additionally he is an adjunct professor at duke university’s fuqua school of business and a board member of the north carolina glaxosmithkline foundation mr abercrombie’s executive experience in the pharmaceutical industry and management positions with major pharmaceutical companies provide an excellent background for service on the board back to top fred e cohen md dphil fred e cohen md dphil was appointed to the board in july  in  dr cohen joined tpg capital a private investment firm to initiate and lead tpg’s venture efforts in biotechnology and life sciences he retired from this role at the end of  and now serves as a senior advisor to tpg beginning in  and until his retirement in  dr cohen served as a member of the faculty of university of california san francisco ucsf at ucsf dr cohen served as an internist for hospitalized patients a consulting endocrinologist and as the chief of the division of endocrinology and metabolism his research interests include structure based drug design prion diseases computational biology and heteropolymer chemistry dr cohen received his bs degree in molecular biophysics and biochemistry from yale university his dphil in molecular biophysics from oxford on a rhodes scholarship his md from stanford and his postdoctoral training and postgraduate medical training in internal medicine and endocrinology at ucsf he is a fellow of the american college of physicians and the american college of medical informatics and a member of the american society for clinical investigation and association of american physicians dr cohen was elected to the institute of medicine of the national academy of sciences in  and the american academy of arts and sciences in  currently dr cohen also serves on the board of directors of genomic health inc veracyte inc tandem diabetes care inc five prime therapeutics inc roka bioscience inc urogen pharma ltd and caredx inc as well as on the boards of several privately held companies dr cohen’s extensive expertise in the pharmaceutical industry private investment expertise and experience serving on boards of biotechnology companies contribute valuable insight and experience to the board back to top stanley c erck stanley c erck was appointed to the board in december  mr erck has over  years of executive leadership experience in the pharmaceutical industry mr erck has served as president ceo and director of novavax inc a publicly traded biopharmaceutical company since  having previously served as executive chairman from  to  and he has served as a director of novavax since  from  through  mr erck served as president and chief executive officer of iomai corporation a biopharmaceutical company leading the company through an initial public offering and a merger with intercell ag an austrian vaccine company and through the development of a latestage infectious disease product candidate prior to iomai mr erck served as president and chief executive officer of procept inc a publicly traded immunology company as vice president corporate development at integrated genetics inc now genzyme corp and in management positions within baxter international inc in addition to novavax mr erck currently sits on the board of directors of maxcyte inc a publicly traded company developing cell based medicines he received his undergraduate degree from the university of illinois and his mba from the university of chicago graduate school of business mr erck’s executive experience in the biotech industry and his management positions with major pharmaceutical companies including his experience with latestage product candidate development provide an excellent background for service on the board back to top nancy hutson phd dr hutson was appointed to the board in january  bringing over  years of experience as a seasoned professional and leader within the pharmaceutical industry she retired from pfizer inc in  after spending  years in several research and leadership positions most recently serving as senior vice president of global research  development rd as well as director of pfizer’s pharmaceutical rd site grotonnew london laboratories currently dr hutson currently serves on the board of directors for cubist pharmaceuticals inc and endo international plc the scientific advisory board of hatteras venture partners and is an active member on the board of directors for planned parenthood of connecticut she is also involved in several professional societies including but not limited to the american association for the advancement of science and the american physiological society dr hutson received a bachelor of arts degree from illinois wesleyan university and a phd in physiology from vanderbilt university back to top kenneth b lee jr kenneth b lee jr was appointed to the board in june  mr lee has over  years of experience counseling management teams boards of directors and investors of technologybased companies worldwide he is currently a general partner with hatteras venture partners llc a venture capital fund focusing on life science companies which he joined in  previously he was president of am pappas  associates llc following  years with ernst  young llp where he was most recently managing director of the firm’s health sciences corporate finance group and at one time served as the national director of the life sciences practice mr lee received a bachelor of arts degree from lenoirrhyne college and an mba from the university of north carolina at chapel hill mr lee is currently on the board of directors of aralez inc and serves on the board of a private company clinipace previously mr lee served on the boards of abgenix cv therapeutics inspire pharmaceuticals maxygen osi pharmaceuticals and clinverse he has served in various leadership capacities on these boards including chairman of the board independent lead director and chairman of audit and compensation committees mr lee’s experience advising biotechnology companies regarding financial and partnering strategies his extensive background in finance and his experience serving on the boards of biotech companies contribute valuable insight and experience to the board back to top sanj k patel sanj k patel is the chairman and ceo of kiniksa pharmaceuticals which was formed in  to develop therapies for patients with devastating diseases and unmet medical need he brings more than  years of experience in the pharmaceutical and biotech industries and has a combination of scientific clinical and commercial skills sanj k patel created synageva in june  to focus on rare diseases and designed and initiated its lead program kanuma® for lysosomal acid lipase deficiency lal deficiency in july  kanuma was approved globally in  as the first therapy for patients suffering from lal deficiency he took the company public on the nasdaq global market in november  and raised over  billion in capital in less than  years in june  synageva was sold to alexion pharmaceuticals for b including cash which represented the highest premium ever paid for a biotech company valued over b prior to synageva he was at genzyme corporation  where most recently he was the head of us sales marketing and commercial operations for genzyme therapeutics franchise and led the us launch of myozyme® in addition to sales and marketing responsibility for cerezyme® fabrazyme® and aldurazyme® previously sanj held several crossfunctional senior leadership roles at genzyme including vice president clinical research and head of the global clinical research operations council for all genzyme divisions including therapeutics oncology and transplant he was responsible for clinical operations and development for all crossbusiness genzyme products and was instrumental in the path to commercialization of several treatments notably sanj led the fabrazyme® clinical operations team and development program to fda approval in april  prior to genzyme sanj held roles in clinical research and commercial operations with increasing levels of responsibility at burroughs wellcome hoechst marrion roussel and fujisawaotsuka pharmaceuticals sanj obtained his bsc with honors in biotechnology from the university of the south bank london he completed his management and business studies at ealing college london and his pharmacology research program at the wellcome foundation sanj is a member of the board of directors for syros pharmaceuticals and biocryst pharmaceuticals both publicly traded biotechnology companies he is also the founder and director of the sanj k patel and family foundation a philanthropic organization that supports various charities supporting patients with rare and devastating diseases back to top jon p stonehouse jon p stonehouse joined biocryst in january  as chief executive officer and director he was also named president in july  prior to joining the company he served as senior vice president of corporate development for merck kgaa a pharmaceutical company since july  his responsibilities included corporate mergers and acquisitions global licensing and business development corporate strategy and alliance management prior to joining merck kgaa mr stonehouse held a variety of roles at astra merckastrazeneca mr stonehouse began his career in the pharmaceutical industry as a sales representative and held increasing sales leadership positions at merck  co inc in  and  respectively mr stonehouse joined the advisory boards of precision biosciences inc a private biotechnology company and genscript a private bioservices company also in december  he joined the board of directors of bellicum pharmaceuticals inc a publicly traded clinical stage biopharmaceutical company focused on novel cellular immunotherapies mr stonehouse earned his bs in microbiology at the university of minnesota as chief executive officer and president of biocryst mr stonehouse brings to the board an intimate knowledge of our business and his executive experience in a variety of capacities at major pharmaceutical companies provides industryspecific operational experience that is beneficial to the board back to top abercrombie george b  insider stock trading  openinsider sector all sectors group by sector aerospace agriculture automobile building business services chemical electrical energy fashion financial food  beverage fund healthcare household insurance machinery media metals mining other personal services real estate retail technology telecom transportation utility industry all industries group by industry insiders filings all purchases sales cik   address po box  chapel hill nc   results links secyahoogooglefinviztradingviewstockchartsstocktwitsdownload csv tc stat stk ins fil d w m q h y avg pretpwins filing date t date ticker issuerinc sector indindustry owner ost rel title t tval price l qty oc own h ry ry rm rm rw rw rd rd fd fw fm fm fm fy  bcrxbiocryst pharmaceuticals incdehealthbioprdbiological products no diagabercrombie george bncdmdd  bcrxbiocryst pharmaceuticals incdehealthbioprdbiological products no diagabercrombie george bncdpd  bcrxbiocryst pharmaceuticals incdehealthbioprdbiological products no diagabercrombie george bncdpnewd  isphinspire pharmaceuticals incdehealthdrugpharmaceutical preparationsabercrombie george bncdmdd dderivative transaction in filing usually option exercise mmultiple transactions in filing earliest reported transaction date and weighted average transaction price aamended filing eerror detected in filing s  salesale of securities on an exchange or to another person s  saleoesale of securities on an exchange or to another person after option exercise f  taxpayment of exercise price or tax liability using portion of securities received from the company p  purchasepurchase of securities on an exchange or from another person return to top contact copyright   openinsidercom all rights reserved ziopharm elects george b abercrombie former ceo of hoffmannla roche to board of directors  business wire ziopharm elects george b abercrombie former ceo of hoffmannla roche to board of directors  dr murray brennan named chairman of board  april    am eastern daylight time new yorkbusiness wireziopharm oncology inc nasdaq ziop announced today the appointment of george b abercrombie to its board of directors mr abercrombie will serve as a member of the board’s compensation committee as well as the nominating and corporate governance committee additionally dr murray brennan was elected chairman of the board mr abercrombie most recently served as the president and chief executive officer of hoffmannla roche roche north america and has more than  years experience in the pharmaceutical industry he was responsible for roche’s us and canadian pharmaceuticals business under mr abercrombie’s leadership the value of roche’s us business increased achieving leading market share positions for key marketed products in joining the ziopharm board george will also have the opportunity to continue his relationship with dr larry norton a consultant partner to ziopharm with whom he worked closely at roche and while dr norton was the president of asco prior to joining hoffmannla roche inc in  mr abercrombie held the position of senior vice president commercial operations at glaxo wellcome inc and prior to joining glaxo held progressively senior positions at merck and company in merck’s human health division in the united states during his distinguished career he has testified as an expert witness on numerous occasions in front of both houses of the us congress mr abercrombie began his career as a pharmacist after receiving a bachelor’s degree in pharmacy from the university of north carolina and earned his mba from harvard university he has served on many boards and organizations throughout his career including the phrma pharmaceutical research and manufacturers of america board of directors the johns hopkins school of hygiene and the public health advisory project hope board of directors and the duke university fuqua school of business health sector advisory board among others “given george’s extensive knowledge and understanding of the development and commercialization of pharmaceutical products across a wide range of indications including those for cancerrelated therapies he will be an invaluable addition to the ziopharm team” stated dr murray brennan chairman of the board “ziopharm will no doubt benefit from george’s wisdom and experience and we are extremely pleased to have him on board at this important transformational stage of the company’s growth and development” “this is really an exciting time for ziopharm and me i am thrilled to be joining this team of enormously impressive professionals who are developing promising medicines to treat cancer” commented mr abercrombie “i look forward to contributing to ziopharm’s success as we build value for patients shareholders and the healthcare system” about ziopharm oncology inc ziopharm oncology is a biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of cancer drugs the company is currently focused on three clinical programs palifosfamide zymafostm or zio references a novel composition tris formulation that comprises the functional active metabolite of ifosfamide a standard of care for treating sarcoma lymphoma testicular and other cancers palifosfamide delivers only the cancer fighting component of ifosfamide it is expected to overcome the resistance seen with ifosfamide and cyclophosphamide two of the most commonly used dnaalkylating drugs used to treat cancers palifosfamide does not have the toxic metabolites of ifosfamide that cause the debilitating side effects of “fuzzy brain” encephalopathy and severe bladder inflammation it may also have other advantages intravenous palifosfamide is currently in a randomized phase ii trial to treat unresectable or metastatic soft tissue sarcoma in the front and secondline setting with the company having reported interim positive results in late  a registration trial in the same setting is expected to initiate following us food and drug administration fda review in the first half of this year an oral form of palifosfamide has been developed preclinically to the investigational new drug application stage darinaparsin zinapartm or zio is a novel mitochondrialtargeted agent organic arsenic being developed for the treatment of various hematologic and solid cancers preclinical and clinical studies to date have demonstrated that darinaparsin is considerably less toxic than inorganic arsenic particularly with regard to cardiac toxicity the company has reported favorable results from a phase ii trial with ivadministered darinaparsin in lymphoma particularly peripheral tcell lymphoma “ptcl” at the american society of clinical oncology asco in may of  which would serve as the basis for ongoing clinical study in ptcl following regulatory review and available financial resources phase i trials with the oral form are ongoing in both hematological malignancies and solid tumors indibulin zybulintm or zio is a novel oral tubulin binding agent that targets both mitosis and cancer cell migration in addition indibulin is expected to have several potential benefits including oral dosing application in multidrug resistant tumors no neuropathy and minimal overall toxicity in multiple phase i trials in cancer patients oral indibulin has been administered both as a single agent and in combination with favorable activity and a promising safety profile that does not include the neurotoxicity seen with all of the other classes of tubulin binding agents most recently results of oral indibulin in combination with oral capecitabine xeloda® were presented at last year’s american society of clinical oncology asco along with the preclinical findings of a novel dosing schedule conducted under the direction of dr larry norton employing this dosage schedule the company expects to initiate a phase i study early this year in breast cancer patients with the breast team at memorial sloan kettering ziopharm’s operations are located in boston ma with an executive office in new york city further information about ziopharm may be found at wwwziopharmcom ziopg forwardlooking safe harbor statement this press release contains forwardlooking statements for ziopharm oncology inc that involve risks and uncertainties that could cause the companys actual results to differ materially from the anticipated results and expectations expressed in these forwardlooking statements these statements are based on current expectations forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements among other things there can be no assurance that any of the companys development efforts relating to its product candidates will be successful or such product candidates will be successfully commercialized other risks that affect forwardlooking information contained in this press release include the possibility of being unable to obtain regulatory approval of the companys product candidates the risk that the results of clinical trials may not support the companys claims the risk that preclinical or clinical trials will proceed on schedules that are consistent with the company’s current expectations or at all risks related to the companys ability to protect its intellectual property and its reliance on third parties to develop its product candidates risks related to the sufficiency of existing capital reserves to fund continued operations for a particular amount of time and uncertainties regarding the company’s ability to obtain additional financing to support its operations thereafter the company assumes no obligation to update these forwardlooking statements except as required by law contacts ziopharm oncology inctyler cook tcookziopharmcomormediadennis s dobson dsdobsonoptonlinenet release summary ziopharm oncology inc nasdaq ziop announced today the appointment of george b abercrombie to its board of directors contacts ziopharm oncology inctyler cook tcookziopharmcomormediadennis s dobson dsdobsonoptonlinenet search advanced news search advanced news search log in sign up inva george b abercrombie insider trades for innoviva inc bulletin mcdonalds shares gain as earnings report includes strong samestore sales rise » investor alert new york markets open in market snapshot analyst ratings expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close innoviva inc nasdaq inva go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus innoviva inc after hours  quotes are delayed by  min jul    pm inva quoteszigmancomposite   change   volume volume  quotes are delayed by  min quoteszigmancomposite previous close     change   day low day high    week low  week high   insider activity individual george b abercrombie mr george b abercrombie is chief commercial officer  senior vice president at innoviva inc he is on the board of directors at physicians interactive holdings llc biocryst pharmaceuticals inc brickell biotech inc and north carolina glaxosmithkline foundation mr abercrombie was previously employed as an independent director by ocera therapeutics inc an independent director by inspire pharmaceuticals inc president  chief executive officer by hoffmannla roche inc senior vice presidentcommercial operations by glaxo wellcome inc a principal by merck  co inc vice chairman by project hopethepeopletopeople healthfoundation inc president  ceopharmaceuticals operations by roche holding ag and president  chief executive officer by roche laboratories inc he also served on the board at aptus health inc ziopharm oncology inc demerx inc johns hopkins bloomberg school of public health pharmaceutical research  manufacturers of america and tranzyme pharma inc canada he received his undergraduate degree from the university of north carolina at chapel hill and an mba from harvard business school transactions date shares transaction value     derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      award at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      award at  per share      award at  per share      award at  per share  copyright  factset research systems inc all rights reserved source factset fundamentals officers and executives mr michael w aguiar president chief executive officer  director mr eric desparbes chief financial officer  senior vice president dr theodore l witek chief scientific officer  senior vice president mr michael e faerm chief business officer  senior vice president mr george b abercrombie chief commercial officer  senior vice president ms barbara gayle duncan director mr william h waltrip chairman mr patrick g lepore independent director mr paul pepe independent director ms catherine j friedman independent director trending tickers quoteszigmancomposite vuzi quoteszigmancomposite jcp quoteszigmancomposite nugt quoteszigmancomposite jnug quoteszigmancomposite tlt x powered by log in  am edt july   marketstatecountryus new york pre marketstatecountryuk london open marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest atintri started at outperform with  stock price target at raymond james awebmd downgraded to market perform from outperform at raymond james aspectranetics downgraded to market perform from outperform at raymond james asierra bancorp upgraded to outperform from market perform at raymond james aalphabet stock price target raised to  from  at raymond james amcdonalds expects to net restaurant additions of  in  amcdonalds expects to have  experience of the future restaurants in us by end of  abreakingcaterpillar mcdonalds stocks set to add about  points to dow industrials aseagate technologys stock plunges after profit and sales miss ceo change aneuralstem stock halted on news of midstage clinical trial miss afreeportmcmoran shares gain  after company swings to a profit in q ainvesting lessons from edward thorp quant pioneer and card counter awe’re reaching the dangerous ninth inning for commercial real estate aneuralstem shares halted premarket for news pending awhat the solar eclipse on aug  will mean for stocks amcdonalds shares rise after earnings revenue beat estimates aseagate technologys stock plunges  premarket after q results ceo transition abarnes  noble shares rocket  premarket after activist shareholder urges sale awells fargo released client data company discloses afreeport mcmoran q adj eps  cents factset consensus  cents loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  insider trading  abercrombie george b  form  sec filings home  archives  products  about  contact  faq  new user sign up  sign in form  filings insider buys significant buys penny stocksinsider buying insider sales insider buy sell ratios stock options insider tradingstock screener insider tradinggraph view insider watch sec filings insider trading  abercrombie george b select time period  month  months  months  months  year  years  years  years all data       google     yahoo send this page to   blog    digg    reddit    facebook    stumble    delicious enter stock ticker symbol or cik cik lookup search by company or insider name insiders might sell their shares for any number of reasons but they buy them for only one they think the price will rise  peter lynch  what is insider trading email a friend  historical filings delayed by  months new user sign up for real time data existing user sign in stock options exercise award grant conversion transactiondate reporteddate exercisableexpiration company symnbol insiderrelationship sharestraded conversionprice sharesowned filing tax withholding  pm nana innoviva inc inva abercrombie george bsr vp  chief comm officer   direct view tax withholding  pm nana innoviva inc inva abercrombie george bsr vp  chief comm officer   direct view option award  pm  biocryst pharmaceuticals inc bcrx abercrombie george bdirector   direct view tax withholding  pm nana innoviva inc inva abercrombie george bsr vp  chief comm officer   direct view tax withholding  pm nana innoviva inc inva abercrombie george bsr vp  chief comm officer   direct view option award  pm nana innoviva inc inva abercrombie george bsr vp  chief comm officer   direct view option award  pm  biocryst pharmaceuticals inc bcrx abercrombie george bdirector   direct view   secformcom all rights reserved archives        tue  jul    sec is the us securities and exchange commission edgar is a trademark of the sec secformcom is not affiliated with or approved by the us securities and exchange commission sec terms of use  privacy statement  george abercrombie  glaxo wellcome inc  zoominfocom abercrombie  fitch  authentic american clothing since  abercrombie  fitch abercrombie kids today only all shorts   under  free shipping over  today only all shorts   under see details shop mens shop womens today only  off stellar styles  free shipping over  today only  off stellar styles see details shop boys shop girls saved item saved to your account want your saves to last forever sign in create an account today exclusively online all shorts  and under  and under all shorts  and under  and under don’t miss out on the last chance for summer shorts at this price shop mens shop womens price reflects discount exclusions apply see details price reflects discount exclusions apply see details shop mens shop womens select styles price reflects discount see details select styles price reflects discount see details right place right time style for whatever you’re doing now…and later mens looks womens looks win a trip around the world join or sign in to the af club to enter to win the vacation of a lifetime join now join now sign in sign in †no purchase necessary to enterwin must be  us only void where prohibited employees not eligible ends  max prize value  nights  people   destinations if winner is under  travel companion must be parentlegal guardian additional terms conditions  restrictions apply for complete rules  details visit httpbitlyafsweeps sponsor abercrombie  fitch stores inc  fitch path new albany oh  †no purchase necessary to enterwin must be  us only void where prohibited employees not eligible ends  max prize value  nights  people   destinations if winner is under  travel companion must be parentlegal guardian additional terms conditions  restrictions apply for complete rules  details visit httpbitlyafsweeps sponsor abercrombie  fitch stores inc  fitch path new albany oh  new fits new washes new styles new details all jeans  all jeans  get into our new jeans mens jeans womens jeans in stores  online exclusions apply see details in stores  online exclusions apply see details mens jeans womens jeans it’s not lazyit’s recovery mens lounge womens lounge ready for liftoff new arrivals discover a constellationhorbarer collectionhorbarof allnew and supercool styles ready for fun times infinity shop boys shop girls join the af club and earn points on every purchaseplus access to exclusive offers sales and insider events join the club learn more abercrombie purchase  pickup order any item online select pickup in store at checkout and we’ll have it waiting for you when you arrive shipping’s on us learn more a judge has given final approval to a settlement in a class action lawsuit against abercrombie  fitch relating to  hard copy promotional gift cards that stated no expiration date on the cards abercrombie  fitch which denies any wrongdoing has restored  of the original remaining value on those promotional gift cards which abercrombie  fitch issued as part of a  winter holiday promotion and a  spring promotion and later voided the restored value on the cards may be redeemed at any store of the brand that issued the card or in the case of gilly hicks at hollister until october   for more information about the settlement please visit wwwabercrombieclassactioncom new arrivals mens womens casual allamerican clothing with laidback sophistication shop jeans tees dresses skirts sweaters outerwear fragrance  accessories    microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft abercrombie  fitch  authentic american clothing since  abercrombie  fitch abercrombie kids today only all shorts   under  free shipping over  today only all shorts   under see details shop mens shop womens today only  off stellar styles  free shipping over  today only  off stellar styles see details shop boys shop girls saved item saved to your account want your saves to last forever sign in create an account today exclusively online all shorts  and under  and under all shorts  and under  and under don’t miss out on the last chance for summer shorts at this price shop mens shop womens price reflects discount exclusions apply see details price reflects discount exclusions apply see details shop mens shop womens select styles price reflects discount see details select styles price reflects discount see details right place right time style for whatever you’re doing now…and later mens looks womens looks win a trip around the world join or sign in to the af club to enter to win the vacation of a lifetime join now join now sign in sign in †no purchase necessary to enterwin must be  us only void where prohibited employees not eligible ends  max prize value  nights  people   destinations if winner is under  travel companion must be parentlegal guardian additional terms conditions  restrictions apply for complete rules  details visit httpbitlyafsweeps sponsor abercrombie  fitch stores inc  fitch path new albany oh  †no purchase necessary to enterwin must be  us only void where prohibited employees not eligible ends  max prize value  nights  people   destinations if winner is under  travel companion must be parentlegal guardian additional terms conditions  restrictions apply for complete rules  details visit httpbitlyafsweeps sponsor abercrombie  fitch stores inc  fitch path new albany oh  new fits new washes new styles new details all jeans  all jeans  get into our new jeans mens jeans womens jeans in stores  online exclusions apply see details in stores  online exclusions apply see details mens jeans womens jeans it’s not lazyit’s recovery mens lounge womens lounge ready for liftoff new arrivals discover a constellationhorbarer collectionhorbarof allnew and supercool styles ready for fun times infinity shop boys shop girls join the af club and earn points on every purchaseplus access to exclusive offers sales and insider events join the club learn more abercrombie purchase  pickup order any item online select pickup in store at checkout and we’ll have it waiting for you when you arrive shipping’s on us learn more a judge has given final approval to a settlement in a class action lawsuit against abercrombie  fitch relating to  hard copy promotional gift cards that stated no expiration date on the cards abercrombie  fitch which denies any wrongdoing has restored  of the original remaining value on those promotional gift cards which abercrombie  fitch issued as part of a  winter holiday promotion and a  spring promotion and later voided the restored value on the cards may be redeemed at any store of the brand that issued the card or in the case of gilly hicks at hollister until october   for more information about the settlement please visit wwwabercrombieclassactioncom new arrivals mens womens casual allamerican clothing with laidback sophistication shop jeans tees dresses skirts sweaters outerwear fragrance  accessories    abercrombie kids  authentic american kids clothing since  abercrombie  fitch abercrombie kids today only all shorts   under  free shipping over  today only all shorts   under see details shop mens shop womens today only  off stellar styles  free shipping over  today only  off stellar styles see details shop boys shop girls saved item saved to your account want your saves to last forever sign in create an account today online only  off stellar styles houston we have a problemhorbarthis sale is toooo good shop musthaves in the milky way from graphic tees to shorts shop boys shop girls online only select styles off original prices price reflects discount see details shop boys shop girls online only select styles off original prices price reflects discount see details limited time all jeans  pants  off shop boys shop girls shop boys shop girls in stores  online exclusions apply online price reflects discount see details shop boys shop girls shop boys shop girls in stores  online exclusions apply online price reflects discount see details out of this world tees supersoft super stellar and made for all the play in the youniverse shop boys shop girls shop boys shop girls shop boys shop girls shop boys shop girls shop boys shop girls shop boys shop girls shop boys shop girls shop boys shop girls shop boys shop girls shop boys shop girls join the af club and earn points on every purchaseplus access to exclusive offers sales and insider events join the club learn more abercrombie purchase  pickup order any item online select pickup in store at checkout and we’ll have it waiting for you when you arrive shipping’s on us learn more casual allamerican clothing with laidback sophistication shop jeans tees dresses skirts sweaters outerwear fragrance  accessories    sign up  get  off entire purchase exclusions apply see details email address submit website terms of use privacy policy instant gratification we just sent an offer code to your inbox abercrombie  fitch  authentic american clothing since  abercrombie  fitch abercrombie kids today only all shorts   under  free shipping over  today only all shorts   under see details shop mens shop womens today only  off stellar styles  free shipping over  today only  off stellar styles see details shop boys shop girls saved item saved to your account want your saves to last forever sign in create an account today exclusively online all shorts  and under  and under all shorts  and under  and under don’t miss out on the last chance for summer shorts at this price shop mens shop womens price reflects discount exclusions apply see details price reflects discount exclusions apply see details shop mens shop womens select styles price reflects discount see details select styles price reflects discount see details right place right time style for whatever you’re doing now…and later mens looks womens looks win a trip around the world join or sign in to the af club to enter to win the vacation of a lifetime join now join now sign in sign in †no purchase necessary to enterwin must be  us only void where prohibited employees not eligible ends  max prize value  nights  people   destinations if winner is under  travel companion must be parentlegal guardian additional terms conditions  restrictions apply for complete rules  details visit httpbitlyafsweeps sponsor abercrombie  fitch stores inc  fitch path new albany oh  †no purchase necessary to enterwin must be  us only void where prohibited employees not eligible ends  max prize value  nights  people   destinations if winner is under  travel companion must be parentlegal guardian additional terms conditions  restrictions apply for complete rules  details visit httpbitlyafsweeps sponsor abercrombie  fitch stores inc  fitch path new albany oh  new fits new washes new styles new details all jeans  all jeans  get into our new jeans mens jeans womens jeans in stores  online exclusions apply see details in stores  online exclusions apply see details mens jeans womens jeans it’s not lazyit’s recovery mens lounge womens lounge ready for liftoff new arrivals discover a constellationhorbarer collectionhorbarof allnew and supercool styles ready for fun times infinity shop boys shop girls join the af club and earn points on every purchaseplus access to exclusive offers sales and insider events join the club learn more abercrombie purchase  pickup order any item online select pickup in store at checkout and we’ll have it waiting for you when you arrive shipping’s on us learn more a judge has given final approval to a settlement in a class action lawsuit against abercrombie  fitch relating to  hard copy promotional gift cards that stated no expiration date on the cards abercrombie  fitch which denies any wrongdoing has restored  of the original remaining value on those promotional gift cards which abercrombie  fitch issued as part of a  winter holiday promotion and a  spring promotion and later voided the restored value on the cards may be redeemed at any store of the brand that issued the card or in the case of gilly hicks at hollister until october   for more information about the settlement please visit wwwabercrombieclassactioncom new arrivals mens womens casual allamerican clothing with laidback sophistication shop jeans tees dresses skirts sweaters outerwear fragrance  accessories